WOCKPHARMA · NSE
Not in active coverage. Cited reporting has mentioned Wockhardt, the record of those mentions is below. Your interest is logged; coverage expands by demand.
Wockhardt's consolidated net sales for June 2026 were Rs 929.00 crore, up 25.88% year-over-year from Rs 738.00 crore in June 2025.
Wockhardt's Zaynich became the first New Chemical Entity fully invented, developed and commercialised by an Indian company to win US FDA approval after twenty-five years and roughly US$800 million of research.
This page lists where cited reporting has mentioned Wockhardt. It is not the full dossier: developments here are single mentions, not corroborated records. We compile and cite; we do not opine.
fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.